SMARTCO Select aims to nurture Britain's innovators
The guiding principles of SMARTCO Select were forged in the white heat of Sheffield’s steel industry, according to founder Charles Breese.
Company
LON:SCLP
Scancell is a clinical stage biotech company developing immunotherapies for a cancer-free future by enhancing long-lasting tumour specific immunity. With deep roots in cancer immunology and translational research, the company aims to translate its innovation and creativity to address the need for fast, potent and accessible therapies that are easy to administer in hard-to-treat cancers.
329 stories · page 17 of 17
The guiding principles of SMARTCO Select were forged in the white heat of Sheffield’s steel industry, according to founder Charles Breese.
Archive
A notable riser was Electric Word (LON:ELE), whose shares added 25% as it announced it has agreed to sell its 70% stake in online magazine iGaming Business to Clarion Events for around £13.8mln.
SCIB1 is programmed to seek out and kill microscopic metastatic cells that are carried by the bloodstream to seed around the body.
Archive
Life was sweet in the world of the small cap miners today.
The highly regarded biotech entrepreneur David Evans, who is Scancell’s chairman, said given the strength of the clinical data from SCIB1 and the pipeline of potential products, further investment is warranted and in his words “could add si
Scancell is at the cutting edge of a new arena of cancer medicine called immuno-oncology that, as mentioned earlier, uses the body’s immune system to combat the disease.
Archive
There has been a significant increase in the resources at Yangibana, the rare earths project in Western Australia, Rare Earth Materials (LON:REM) revealed. Total mineral resources have been upped to 71,828 contained tonnes of total rare ear
It is giving no fewer than six presentations on the company's ImmunoBody and Moditope immunotherapy platforms.
Investments and investor services
It was a bad day for companies with the word 'scan' in their name.